Therapeutic Management and Use of Resources and Costs of Spinal Muscular Atrophy in Spain

Study Identifier:
COAV101A1ES05
ClinicalTrials.gov Identifier:
NCT06632730
EudraCT Identifier:
N/A
EU CT Number:
N/A
Sponsor:
Novartis
Study Complete

Study Details

Medical Condition
  • Spinal Muscular Atrophy Type I
  • Spinal Muscular Atrophy Type II
Study Drug
    Date
    Jul 2023 - Nov 2023
    Patient Requirements
    Sex: Female & Male
    Age: N/A - 14 Years
    Requirements Information
    Inclusion and Exclusion Criteria
    Inclusion Criteria
    • Patients diagnosed with SMA type I or SMA type II.
    • Patients with medical records available in the hospital.
    • Patients diagnosed with SMA type I or SMA type II after 2017 for whom a minimum of 6 months of follow-up was available.
    Exclusion Criteria
    • • Patients who participated in an experimental design study except for those in the long-term follow-up period, during the observation period.

    Protocol Summary

    An observational, retrospective, cross-sectional, multicenter study. Real-world data were obtained from medical records of Spanish public hospitals (9 hospitals).

    Trial Locations

    Location
    Status
    Location
    Novartis Pharmaceuticals
    East Hanover, New Jersey, United States, 07936
    Status
    N/A

    Contact Cure SMA

    User Information

    If you have general questions regarding clinical trials or would like to be added to the Cure SMA mailing list to receive communications regarding future registries, studies, or clinical trials in SMA, please fill out the form below. Fields marked with an asterisk (*) are mandatory.

    • Disability Advocate who does not have SMA
    • I am a healthcare provider
    • I am a researcher
    • I have no direct connection to SMA
    • I have SMA
    • I lost a child to SMA
    • My child has SMA
    • Someone close to me has/had SMA
    • Australia
    • Belgium
    • Brazil
    • Canada
    • Chile
    • China
    • Colombia
    • Croatia
    • Czech Republic
    • Denmark
    • Estonia
    • France
    • Germany
    • Greece
    • Hong Kong
    • Hungary
    • India
    • Ireland
    • Israel
    • Italy
    • Japan
    • Lebanon
    • Malaysia
    • Mexico
    • Netherlands
    • Norway
    • Poland
    • Portugal
    • Puerto Rico
    • Qatar
    • Republic of Korea
    • Romania
    • Russian Federation
    • Saudi Arabia
    • Serbia
    • Singapore
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Taiwan, Province of China
    • Thailand
    • Ukraine
    • United Kingdom
    • United States
    • Vietnam
    This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.